(go to content)

Castellano | Euskara | Français | English

 Imagen decorativa
DTB: Vol 19, No 3. May - July 2011

Content tools

Share it

  • Meneame
  • Delicious
  • Twitter
  • Google
  • Facebook

What role can dabigatran, rivaroxaban and apixaban play in the future?

Dabigatran, rivaroxaban and apixaban have shown to be non inferior to warfarin. However these drugs might not be indicated in a considerable group of patients, especially the elderly and those with important liver or renal impairment. The long-term safety profile is unknown and safety alerts have been published in different countries. The high cost of these agents may limit their use.
Use of the new anticoagulants remains unjustified in those patients who tolerate warfarin treatment and whose monitoring is stable. Independent clinical trials are needed to define the role of new anticoagulant agents in the treatment of non valvular AF.


  • Miguel Ángel Imízcoz. Cardiology Department. Navarre Hospital Complex. Spain

  • Juan Erviti. Drug Information Unit. Navarre Regional Health Service. Spain
Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)






Government of Navarre

Contact us | Accessibility | Legal notice | Site map